Human IL-6R (CD126) Antibody - Tocilizumab Biosimilar

Human IgG1 - CAS#375823-41-9

ABOUT

Anti-IL-6R antibody - Tocilizumab biosimilar - CAS #375823-41-9

Anti-hIL-6R-hIgG1 a biosimilar research antibody to Tocilizumab. Tocilizumab (RG-1569, rhPM-1), also known as TCZ, is a humanized IgG1κ monoclonal antibody (mAb) directed against both soluble and membrane-bound human interleukin-6 receptor (IL-6R). Tocilizumab is FDA-approved for the treatment of inflammatory diseases and conditions, such as rheumatoid arthritis (RA) and cytokine release syndrome.

More details More details

 

Anti-hIL-6R-hIgG1 comprises the variable region of Tocilizumab and a human IgG1 constant region with high effector functions. For applications requiring low Fc effector activity, InvivoGen also offer Anti-hIL6R-To-hIgG1NQ, aTocilizumab-based research antibody with a mutated Fc silent constant region.

This antibody can be used with HEK-Blue™ IL-6 cells for screening and neutralization assays to block recombinant human IL-6-induced signaling (see figure).

Key features

  • Each lot is functionally tested and validated
  • The complete sequence of the antibody construct has been verified
  • Absence of endotoxins determined by the EndotoxDetect™ assay

All products are for research use only, and not for human or veterinary use.

Tocilizumab blocks IL-6R signaling
Tocilizumab blocks IL-6R signaling

Details

IL-6R background

Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6  to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].

 

References:

1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.

SPECIFICATIONS

Specifications

Target

Interleukin 6 receptor (IL-6R)

Target species

Human

Antibody applications
Neutralization assay
Isotype
hIgG1
kappa
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Tocilizumab (Anti-hIL-6R-hIgG1, kappa)
Source
CHO cells
Purification
Protein G
Formulation buffer

0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.

Preservative
Azide-free
Aggregation

< 5%

Reconstitution buffer
Sterile water
Sterility

Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and TLR4 cellular assays.

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL6R-To-hIgG1
  • Cat code: 
    hil6rto-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

    Caution:

    • Avoid repeated freeze-thaw cycles

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?